Research and Markets: An Extensive Analysis of Future Perspectives in Cancer Immunotherapy.
Business Editors
DUBLIN, Ireland--(BUSINESS WIRE)--May 10, 2004
Research and Markets (http://www.researchandmarkets.com) has announced the addition of Future Perspectives in Cancer Immunotherapy to their offering.
This report analyses more than 675 industry related cancer immunotherapy R&D projects including more than 425 clinical trials of which 60 are in phase III. The latest meeting held by the American Society of Clinical Oncology, the American Association Cancer Research and the American Society of Hematology are also covered in this extensive analysis.
"Future Perspectives in Cancer Immunotherapy" is a summarized version of our more extensive report "A Shift in Cancer Immunotherapy Strategies?". Still, it provides the essence and main conclusive parts and will work as a guideline for trend analysis, even though the bulk of data which included in the larger report has been removed. If your primary interest is to read the more conclusive and analytical parts, this report is an excellent choice. It provides a broad overview of current efforts in cancer immunotherapy R&D as well as concludes and assesses major factors important for success. Further, it describes the ongoing efforts in developing innovative immunotherapies for the treatment of cancer. Trends within the industry are identified and analyzed.
The contents of this report are structured into several well-defined therapeutic concepts. This includes major therapeutic strategies such as monoclonal antibodies, anti-idiotypic antibodies, tumor antigens, cellular vaccines, gene therapy, immunostimulatory drugs and other biological drugs. The comparison of therapeutic strategies, targets and cancer indications reveals differences between disease and treatment.
The concept of utilizing the immune system for the treatment of cancer has been tried for some time without any direct breakthrough success. So far "passive" immunotherapy has experienced most success, with antibody and cytokine therapy leading the way. One example is Rituxan, a "drug" that has seen its revenue grow from $152 million in 1998 to more than $1 billion in 2002. Other immune-based therapies that have already reached the market is Zevailn, Bexxar, Campath, OncoVax and Erbitux.
Other cancer vaccine strategies that are on the way are Actimmune, Allovectin-7, Avicine, BEC2, Canvaxin, CeaVac, Gastrimmune, GMK, LymphoCide, Melacine, Ovarex, Oncophage, Osidem and. These treatments are all FDA approved or in late stage clinical trails. Immunotherapy has for some time been heralded as a breakthrough approach for cancer treatment. Although the potential of this strategy remains solid, there are still a number if missing.
For more information visit http://www.researchandmarkets.com/reports/c1885
DUBLIN, Ireland--(BUSINESS WIRE)--May 10, 2004
Research and Markets (http://www.researchandmarkets.com) has announced the addition of Future Perspectives in Cancer Immunotherapy to their offering.
This report analyses more than 675 industry related cancer immunotherapy R&D projects including more than 425 clinical trials of which 60 are in phase III. The latest meeting held by the American Society of Clinical Oncology, the American Association Cancer Research and the American Society of Hematology are also covered in this extensive analysis.
"Future Perspectives in Cancer Immunotherapy" is a summarized version of our more extensive report "A Shift in Cancer Immunotherapy Strategies?". Still, it provides the essence and main conclusive parts and will work as a guideline for trend analysis, even though the bulk of data which included in the larger report has been removed. If your primary interest is to read the more conclusive and analytical parts, this report is an excellent choice. It provides a broad overview of current efforts in cancer immunotherapy R&D as well as concludes and assesses major factors important for success. Further, it describes the ongoing efforts in developing innovative immunotherapies for the treatment of cancer. Trends within the industry are identified and analyzed.
The contents of this report are structured into several well-defined therapeutic concepts. This includes major therapeutic strategies such as monoclonal antibodies, anti-idiotypic antibodies, tumor antigens, cellular vaccines, gene therapy, immunostimulatory drugs and other biological drugs. The comparison of therapeutic strategies, targets and cancer indications reveals differences between disease and treatment.
The concept of utilizing the immune system for the treatment of cancer has been tried for some time without any direct breakthrough success. So far "passive" immunotherapy has experienced most success, with antibody and cytokine therapy leading the way. One example is Rituxan, a "drug" that has seen its revenue grow from $152 million in 1998 to more than $1 billion in 2002. Other immune-based therapies that have already reached the market is Zevailn, Bexxar, Campath, OncoVax and Erbitux.
Other cancer vaccine strategies that are on the way are Actimmune, Allovectin-7, Avicine, BEC2, Canvaxin, CeaVac, Gastrimmune, GMK, LymphoCide, Melacine, Ovarex, Oncophage, Osidem and. These treatments are all FDA approved or in late stage clinical trails. Immunotherapy has for some time been heralded as a breakthrough approach for cancer treatment. Although the potential of this strategy remains solid, there are still a number if missing.
For more information visit http://www.researchandmarkets.com/reports/c1885
 Printer friendly
 Cite/link
 Email
 Feedback
| |
| Publication: | Business Wire |
|---|---|
| Date: | May 10, 2004 |
| Words: | 407 |
| Previous Article: | Nomura Securities Selects VhaYu's Real-Time and Historic Tick-Data Platform for New Trading Infrastructure in New York. |
| Next Article: | ADVISORY/AAA To Honor School Safety Patrollers for Saving Fellow Students' Lives. |